Amicus Therapeutics(FOLD) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates Q2 2024 Total Revenue of $126.7M, a 34% Increase Year-over-Year GalafoldQ2 Revenue of$ 110.8M, up 17% Year-over-Year Pombiliti + OpfoldaQ2 Revenue of $15.9M, up 44% from Q1 2024 Raising 2024 Total Revenue Growth Guidance to 26%-31% at CER and 2024 Galafold Growth Guidance to 14%-18% at CER Narrowing non-GAAP Operating Expense Guidance to$ 345M to $360M Non-GAAP Profitability Achieved in Q2 and H1 2024 with ...